Nvidia's Jensen Huang Banks on AI Biotech Startup Generate Biomedicines

Nvidia's CEO Jensen Huang has a significant stake in Generate Biomedicines, a clinical-stage biotech company. The tech giant's venture arm, NVentures, has invested around $10.4 million in the company through its IPO this February.

Generate Biomedicines' AI platform uses machine-learning architectures to engineer novel protein therapeutics from scratch. Its lead candidate, GB-0895, is currently in phase 3 trials for severe asthma and an early-stage trial in COPD. The company also has a pipeline of dozens of clinical candidates across multiple therapeutic areas.

The biotech's strategic backing and co-development deals with Amgen and Nvidia provide strong institutional validation. However, Generate Biomedicines faces ongoing cash burn and potential dilution before achieving commercial profitability. As a clinical-stage company, it has limited revenue and reported a net loss of $61.7 million in the first quarter.